ImmuCell Unveils New Website
July 17 2017 - 8:00AM
ImmuCell Corporation (Nasdaq:ICCC), a growing
animal health company that develops, manufactures and markets
scientifically-proven products that improve health and productivity
in the dairy and beef industries, today introduced a newly designed
corporate website to better communicate the value proposition that
its products provide for its customers, the investment community
and the media. The site can be accessed at www.immucell.com.
Michael F. Brigham, President and CEO of ImmuCell, said, “We are
excited to unveil the new corporate website. It more
accurately, and graphically, depicts the ability of our products to
maximize the productive capabilities of our customers’ most
important assets, and it communicates the increasingly important
role that our products can play in reducing the amount of
antibiotics in the human food chain.”
ImmuCell markets the First Defense® product
line that provides “immediate immunity” against aggressive
pathogens, including E. coli and coronavirus, in newborn dairy and
beef calves without the use of traditional antibiotics. The
addition of a claim against rotavirus infections is anticipated
(subject to USDA approval) towards the end of the year. The Company
is in the late stages of developing a novel product to address
subclinical mastitis in fully grown milking cows. Mastitis is the
most significant cause of economic loss to the dairy industry
totaling approximately $2 BILLION annually. Subject to FDA
approval, ImmuCell’s product will treat infections in milk
producing cows without the use of traditional antibiotics and
without the standard milk discard requirements for cows treated
with antibiotics, generally reducing the amount of antibiotics in
the milk supply.
About ImmuCell ImmuCell Corporation's
(Nasdaq:ICCC) purpose is to create scientifically-proven and
practical products that improve animal health and productivity in
the dairy and beef industries. ImmuCell has developed products
that provide significant, immediate immunity to newborn dairy and
beef livestock. The Company is developing a novel treatment for
mastitis, the most significant cause of economic loss to the dairy
industry. Press releases and other information about the Company
are available at: (http://www.immucell.com).
Safe Harbor Statement:
This Press Release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to:
projections of future financial performance; the scope and timing
of ongoing and future product development work and
commercialization of our products; future costs of product
development efforts; the estimated prevalence rate of subclinical
mastitis; future market share of and revenue generated by current
products and products still in development; future sources of
financial support for our product development, manufacturing and
marketing efforts; the future adequacy of our own manufacturing
facilities or those of third parties with which we have contractual
relationships to meet demand for our products on a timely basis;
the amount and timing of future investments in facility
modifications and production equipment; the future adequacy of our
working capital and the availability and cost of third party
financing; timing and future costs of a facility to produce the
Drug Substance (active pharmaceutical ingredient) for our novel
mastitis treatment; the timing and outcome of pending or
anticipated applications for regulatory approvals; future
regulatory requirements relating to our products; future expense
ratios and margins; future compliance with bank debt covenants;
future realization of deferred tax assets; costs associated with
sustaining compliance with cGMP regulations in our current
operations and attaining such compliance for the facility to
produce the Drug Substance for our novel mastitis treatment;
factors that may affect the dairy and beef industries and future
demand for our products; the cost-effectiveness of additional sales
and marketing expenditures and resources; the accuracy of our
understanding of our distributors’ ordering patterns; anticipated
changes in our manufacturing capabilities and efficiencies;
anticipated competitive and market conditions; and any other
statements that are not historical facts. Forward-looking
statements can be identified by the use of words such as “expects”,
“may”, “anticipates”, “aims”, “intends”, “would”, “could”,
“should”, “will”, “plans”, “believes”, “estimates”, “targets”,
“projects”, “forecasts” and similar words and expressions. In
addition, there can be no assurance that future developments
affecting us will be those that we anticipate. Such statements
involve risks and uncertainties, including, but not limited to,
those risks and uncertainties relating to difficulties or delays in
development, testing, regulatory approval, production and marketing
of our products, competition within our anticipated product
markets, customer acceptance of our new and existing products,
alignment between our manufacturing resources and product demand,
the uncertainties associated with product development and Drug
Substance manufacturing, actual as compared to expected or
estimated costs of expanding our manufacturing facilities, our
potential reliance upon third parties for financial support,
products and services, changes in laws and regulations, decision
making by regulatory authorities, possible dilutive impacts on
existing stockholders from any equity financing transactions in
which we may engage, currency fluctuations and other risks detailed
from time to time in filings we make with the Securities and
Exchange Commission, including our Quarterly Reports on Form 10-Q,
our Annual Reports on Form 10-K and our Current Reports on Form
8-K. Such statements are based on our current expectations, but
actual results may differ materially due to various factors.
Contacts:
Michael F. Brigham, President and CEO
ImmuCell Corporation
(207) 878-2770
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
(602) 889-9700
iccc@lythampartners.com
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024